Cg Oncology Inc (CGON)

Dec 16, 2024, 4:05 PM EST - 4 weeks ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 2:09 PM EST - 5 weeks ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 12, 2024, 8:19 PM EST - 5 weeks ago

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024, 6:17 AM EST - 5 weeks ago

CG Oncology Announces Proposed Public Offering

Dec 6, 2024, 1:18 PM EST - 6 weeks ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 5, 2024, 7:00 AM EST - 6 weeks ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Aug 30, 2024, 8:00 AM EDT - 5 months ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 10:34 AM EDT - 5 months ago

CG Oncology: Promising Data, But Looks Expensive

Aug 8, 2024, 8:23 AM EDT - 5 months ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 9:19 AM EDT - 6 months ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jun 6, 2024, 12:14 PM EDT - 8 months ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

May 24, 2024, 8:00 AM EDT - 8 months ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 9 months ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 1:04 PM EDT - 9 months ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 3, 2024, 11:23 AM EDT - 9 months ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 26, 2024, 8:00 AM EDT - 9 months ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 24, 2024, 10:00 AM EDT - 9 months ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Mar 28, 2024, 8:00 AM EDT - 10 months ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Feb 22, 2024, 8:55 AM EST - 11 months ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering